Steven Heatherly
Cardiovascular Disease · Madisonville, KYNPI 1922289602
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,567 of the $7,569 with a category attached, or 60.3%. 28 manufacturers reported payments, led by Boston Scientific at 31.5% of the total. Reporting peaked in 2022 at $4,924 and has fallen 95.3% since, to $230 in 2025.
Across 164 payments — averaging $46.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Medtronic$1K
- Abbott$715
- Cvrx, Inc.$614
- Novartis$397
- Bayer$369
- plus $2K from 22 others
Across 594 payments — averaging $251.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$89K
- Medtronic$60K
What the payments were for
- Consulting fees$2003%
- Travel & lodging$2,65335%
- Food & beverage$4,56760%
- Education$1492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 19 | $2,384 |
| Medtronic | 13 | $1,288 |
| Abbott | 17 | $715 |
| Cvrx, Inc. | 9 | $614 |
| Novartis | 22 | $397 |
| Bayer | 11 | $369 |
| Actelion Pharmaceuticals US, Inc. | 11 | $332 |
| Merck | 10 | $292 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $239 |
| E.r. Squibb & Sons, L.L.C. | 9 | $152 |
| Penumbra, Inc. | 1 | $149 |
| AstraZeneca | 5 | $86 |
| Johnson & Johnson(2 entities) | 6 | $81 |
| Alnylam Pharmaceuticals Inc. | 4 | $79 |
| Amgen | 5 | $77 |
| Current Health, Inc. | 1 | $61 |
| Boehringer Ingelheim | 4 | $55 |
| United Therapeutics Corporation | 2 | $31 |
| Philips North America LLC | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Pfizer | 1 | $18 |
| KCI USA, Inc. | 1 | $13 |
| Tactile Systems Technology Inc | 1 | $12 |
| Lundbeck LLC | 1 | $11 |
| Kls-martin L.p. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$1,722
- Barostim Neo System$396
- Adempas$200
- CardioMEMS HF System$153
- Indigo System$149
- Confirm Rx$137
How this compares
$7,569 in reported general payments places this provider in the 80th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 62 | $1,450,646 |
| CamzyosMavacamten | 135 | $1,078,047 |
| VyndaqelTafamidis Meglumine | 43 | $918,257 |
| UptraviSelexipag | 14 | $326,218 |
| JardianceEmpagliflozin | 245 | $235,577 |
| AdempasRiociguat | 13 | $176,244 |
| FarxigaDapagliflozin Propanediol | 121 | $107,511 |
| EntrestoSacubitril/Valsartan | 78 | $76,347 |
| Ambrisentan | 28 | $68,186 |
| Potassium Chloride | 122 | $9,849 |
| Sildenafil Citrate | 26 | $4,761 |
| Bumetanide | 64 | $2,472 |
| Metoprolol Succinate | 202 | $2,259 |
| Torsemide | 65 | $2,113 |
| Spironolactone | 229 | $1,335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel | $18 | $2,368,902105 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $152 | $1,078,047135 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi | $332 | $326,21814 claims |
| Boehringer IngelheimJardiance | $55 | $235,577245 claims |
| BayerAdempas | $369 | $176,24413 claims |
| AstraZenecaFarxiga | $86 | $107,511121 claims |
| NovartisEntresto | $397 | $76,34778 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Madisonville
- Adnan SultanMadisonville$8K
- Amir PirachaLouisville$530K
- Dinesh KalraLouisville$316K
- William SkinnerLexington$312K
- Prabodh MehtaElizabethtown$133K
- John HarrisLouisville$129K
- David MoliternoLexington$115K
- Rohan SamsonLouisville$94K
- Srinivasa AppakonduHazard$91K
- Muhammad AkbarBowling Green$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.